Skip to main content

Table 1 Baseline and clinical characteristics of the 59 patients who were evaluated to validate the 20-item questionnaire

From: Activities of daily living questionnaire from patients’ perspectives in Parkinson’s disease: a cross-sectional study

  Mean ± SD
Number (male-to-female ratio) 59 (22:37)
Age (years) 66.85 ± 8.25
Disease duration (years) 6.14 ± 4.80
Treatment duration (years) 4.43 ± 4.00
The daily dose of levodopa (mg/day) 540.00 ± 296.21
K-MMSE 26.49 ± 2.85
New questionnaire 23.24 ± 22.29
HY stage 2.42 ± 0.58
UPDRS 45.78 ± 18.49
 Mentation 3.26 ± 2.05
 ADL 11.88 ± 6.22
 Motor 27.91 ± 11.05
 Complications 2.73 ± 2.97
SEADL 77.59 ± 15.89
BDI 22.38 ± 11.53
PDQL 115.53 ± 39.93
 Parkinson’s symptoms 42.51 ± 14.14
 Systemic symptoms 25.27 ± 9.64
 Social function 19.21 ± 7.18
 Emotional function subscore 28.54 ± 10.80
ADQ 19.21 ± 12.42
FSS 36.20 ± 15.69
  1. K-MMSE Korean Mini-Mental Status Examination, HY Hoehn and Yahr, UPDRS Unified Parkinson’s Disease Rating Scale, ADL Activities of Daily Living, SEADL Schwab and England ADL, BDI Beck’s Depression Inventory, PDQL Parkinson’s Disease Quality of Life, ADQ Autonomic Dysfunction Questionnaire, FSS Fatigue Severity Scale